Equities

Sareum Holdings PLC

Sareum Holdings PLC

Actions
  • Price (EUR)0.063
  • Today's Change-0.007 / -10.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 03 2021.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.50m
  • Incorporated2004
  • Employees6.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 122 349 7700
  • Fax+44 122 349 7701
  • Websitehttp://www.sareum.co.uk/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.